Advertisement

Picture Eurasanté BioFIT 2017 Strasbourg France November 600x60px
Document › Details

Epigenomics AG. (8/30/17). "Press Release: Epigenomics Commences Post Approval Study on Epi proColon". Berlin & Germantown, MD.

Region Region United States (USA)
Organisations Organisation Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY)
  Group Epigenomics (Group)
  Organisation 2 FDA (US Food and Drug Administration)
  Group United States (govt)
Products Product Epi proColon® blood test
  Product 2 clinical research
Persons Person Hamilton, Gregory (Greg) (Epigenomics 201607– CEO before AltheaDx + Enigma Diagnostics + Third Wave + Hologic)
  Person 2 Bull, David (Epigenomics 201703 Director of Marketing)
     


Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), today announced the initiation of a Post Approval Study (PAS), Performance of Epi proColon in Repeated Testing in the Intended Use Population (PERT) - NCT03218423.

The PERT trial is being conducted in concert with the US Food and Drug Administration (FDA) following the 2016 Post Market Approval (PMA) of the blood based Epi proColon screening test for colorectal cancer. Epi proColon is intended for patients who are unwilling or unable to be screened with other methods including colonoscopy and take-home stool tests.

The trial is designed to assess the participation and performance of the Epi proColon test in consecutive years as well as the willingness of patients with a positive Epi proColon test to be referred to colonoscopy. The multi-center PERT trial is initiating at Beaumont Hospital in Royal Oak MI, Geisinger Clinic in Danville PA, West Virginia University in Morgantown WV and three additional centers of excellence within the US. The study will enroll 4,500 subjects over the next three years, with anticipated completion in 2022.

"Epi proColon meets a critical clinical need in the colorectal cancer screening landscape. One in three Americans are still unscreened despite awareness campaigns and sophisticated patient navigation systems. A blood test addresses the typical patient barriers associated with colonoscopy and stool tests," stated Greg Hamilton, CEO of Epigenomics. "This trial will be instrumental in defining the longer-term acceptance and performance of Epi proColon. We are confident that the results will further demonstrate the value of Epi proColon in reaching the millions of eligible Americans that have not yet been screened."


About Epigenomics

Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology. The company develops and commercializes diagnostic products across multiple cancer indications with high medical need. Epigenomics' lead product, Epi proColon, is a blood-based screening test for the detection of colorectal cancer. Epi proColon has received approval from the U.S. Food and Drug Administration (FDA) and is currently marketed in the United States, Europe, and China and selected other countries. Epigenomics' second product, Epi proLung(R), is in development as a blood-based test for lung cancer detection.


For more information, visit www.epigenomics.com.

Contact in the U.S.
David Bull
Director of Marketing
Phone: 240.912.6430
David.Bull@Epigenomics.com

Contact Epigenomics AG
Peter Vogt
Vice President Corporate Communication & Investor Relations
Epigenomics AG
Geneststraße 5
10829 Berlin
Phone +49 (0) 30 24345 386
ir@epigenomics.com

   
Record changed: 2017-09-06

Advertisement

Picture BIO Deutschland EBDC 2017 Heidelberg 600x60px

More documents for Epigenomics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner HealthCapital BIO-Europe 2017 Germany November 600x60px




» top

Advertisements

Picture Berlin Partner HealthCapital BIO-Europe 2017 Germany November 120x240px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px 22 Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA Save USD100 120x180px Picture Berlin Partner HealthCapital BIO-Europe 2017 Germany November 120x240px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px 41 Picture EBD Group BioPharm America 2017 BPA Boston MA Save USD100 120x180px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px